FINNENCE ▪ THE WIRE FILE
THE WIRE · № 66666
News■ Unclear/unknown
Lundbeck presents Phase Ib data for Lu AF28996 in advanced Parkinson's disease, as Phase II trial begins
KINDNews
DIRECTION■ Unclear/unknown
SOURCES2
ENTITIES1
STORY SIZESTANDALONE
FIRST SEEN2026-10-06 06:16 UTC
LAST UPDATE2026-10-06 06:19 UTC
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
Phase Ib safety data with Phase II starting is routine pipeline progress, not a commercial catalyst.
Pipeline progress, but far from revenue
CATALYST TO WATCH
Phase II efficacy readout timing
MAIN RISK
Adverse events could halt development
FULL DISPATCH
Results from an 18-week, open-label Phase Ib trial of investigational Lu AF28996 in people with advanced Parkinson's disease are being presented at MDS 2026 The trial provided initial safety and tolerability data for Lu AF28996, with most treatment-emergent adverse events reported as mild...
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
AFFECTEDHealthcare
04 RECEIPTS
THE SOURCE RECORD.
2 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare
Inflation Reduction Act side effect could harm cancer care2026-10-06 06:02 UTC
Inflation Reduction Act side effect could harm cancer care2026-10-06 06:02 UTC
→CORRELATIONshares Healthcare
Northwest Biotherapeutics Announces Keynote Presentation on Harnessing Immunity: A Personalized, Multi-Target Approach to Cancer At the UK National Health Service Annual Oncology Conference2026-10-06 07:00 UTC
Northwest Biotherapeutics Announces Keynote Presentation on Harnessing Immunity: A Personalized, Multi-Target Approach to Cancer At the UK National Health Service Annual Oncology Conference2026-10-06 07:00 UTC
←CORRELATIONshares Healthcare
GE HealthCare is expected to announce Monday a $945 million cash purchase of a manufacturer of radioactive substances used in medical imaging procedures like PET scans2026-10-05 11:32 UTC
GE HealthCare is expected to announce Monday a $945 million cash purchase of a manufacturer of radioactive substances used in medical imaging procedures like PET scans2026-10-05 11:32 UTC
←CORRELATIONshares Healthcare
In test of investors' appetite, Lilly-connected TRex Bio plots $153 million IPO2026-10-05 19:31 UTC
In test of investors' appetite, Lilly-connected TRex Bio plots $153 million IPO2026-10-05 19:31 UTC
←CORRELATIONshares Healthcare
Pharma firms closed biopharma buyouts worth over a hundred billion dollars in the first half of the year, racing to replace top selling medicines worth around $400 billion before patents expire. Leah Bennett of Concurrent explains2026-10-05 20:15 UTC
Pharma firms closed biopharma buyouts worth over a hundred billion dollars in the first half of the year, racing to replace top selling medicines worth around $400 billion before patents expire. Leah Bennett of Concurrent explains2026-10-05 20:15 UTC
←CORRELATIONshares Healthcare
AstraZeneca CEO says Summit drug could drive next generation of cancer combinations2026-10-05 20:30 UTC
AstraZeneca CEO says Summit drug could drive next generation of cancer combinations2026-10-05 20:30 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.